Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended duration short-interfering RNA meant to reduce lipoprotein (a).
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
